This incidence contrasts with larger studies with PD1 inhibition monotherapy reporting between 6% and 10% of patients experiencing hypothyroidism (Table 1) [2–4] The studies in Table 1 were selected to best match the phase II combination therapy trial in regard to PD1 monotherapy and follow-up time. Here, PDCD1 is linked to hypothyroidism.